Medication vs. Natural

The Hidden Risks of Common Sleep Medications: What You Need to Know

Beyond the side effects on the label — cognitive impairment, fall risk, respiratory effects, and the psychological dependency trap.

By The Sleep Editorial Team·January 21, 2026·8 min read·Reviewed by Dr. Sarah Chen, MD, Board-Certified Sleep Medicine

Hidden risks of sleep medications — Photograph for Sleep Editorial.

Sleep medications are among the most frequently prescribed drugs in the United States. Tens of millions of Americans take some form of sleep aid — prescription, over-the-counter, or supplement — on a regular basis. Yet despite their ubiquity, most people who take these medications have limited knowledge of their mechanisms, their risks, and the ways those risks evolve over time. The conversation most patients have with prescribers before starting a sleep medication is brief. The conversation they need is considerably longer.

This article examines the risks of the most commonly used sleep medications in evidence-based detail: not to argue that no one should ever use sleep aids, but to provide the information necessary for genuinely informed decisions about drugs that alter brain chemistry in ways that have lasting consequences for some users.

Benzodiazepines: The Legacy Sedatives

Benzodiazepines — including diazepam (Valium), lorazepam (Ativan), temazepam (Restoril), and triazolam (Halcion) — were among the most prescribed drugs in the world during the 1970s and 1980s. They work by enhancing the activity of GABA, the brain's primary inhibitory neurotransmitter, producing sedation, muscle relaxation, and anxiety reduction.

For acute insomnia — particularly stress-related sleeplessness following a specific trigger — short-term benzodiazepine use can be appropriate. The risks accumulate with duration.

Tolerance and Physical Dependence

Benzodiazepines produce tolerance relatively quickly. Within weeks of nightly use, the brain adjusts to the presence of the drug by downregulating GABA receptor sensitivity — meaning the same dose produces diminishing effects. Users find themselves needing higher doses to achieve the same sleep benefit. Physical dependence can develop within weeks of regular use, meaning the brain now requires the drug to maintain normal function. Discontinuing benzodiazepines abruptly after physical dependence has developed can produce serious withdrawal symptoms, including rebound insomnia dramatically worse than the original problem, anxiety, irritability, seizures, and — in severe cases — potentially life-threatening withdrawal syndrome.

Cognitive Impairment

Benzodiazepines impair memory consolidation and cognitive performance, particularly in older adults. Long-term use has been associated with persistent cognitive deficits that may not fully resolve after discontinuation. A large prospective study in France found that benzodiazepine use was associated with a significantly increased risk of dementia diagnosis, though the causal direction of this association remains debated in the literature.

Fall Risk in Older Adults

The sedating and muscle-relaxant effects of benzodiazepines increase fall risk significantly, particularly in older adults. Falls in this population are a leading cause of injury, disability, and death. The American Geriatrics Society's Beers Criteria — a guideline for medication use in older adults — lists all benzodiazepines as potentially inappropriate for older patients due to this risk profile.

Z-Drugs: The Next Generation with Similar Problems

The Z-drugs — zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta) — were introduced in the late 1980s and 1990s with the marketing premise that they were safer than benzodiazepines. They work through the same GABA mechanism but with somewhat greater selectivity for the sleep-promoting receptor subtypes. In practice, their risk profiles are more similar to benzodiazepines than their manufacturers initially suggested.

Complex Sleep Behaviors

The FDA issued a black box warning for Z-drugs in 2019 specifically because of reports of complex sleep behaviors — actions performed while in a sedated, not-fully-awake state. These include sleepwalking, sleep driving, preparing and eating food, making phone calls, and having sex — all with no memory of the activity. Serious injuries and deaths have been reported. The FDA requires that the black box warning state that these behaviors can occur with the first dose, and that patients with a history of complex sleep behaviors should not take these medications.

Rebound Insomnia

Abrupt discontinuation of Z-drugs after regular use typically produces rebound insomnia — a period of sleep dramatically worse than baseline. This rebound reinforces dependence by creating a strong incentive to resume the medication. Many patients describe a pattern in which they cannot conceive of sleeping without medication, not because of any pre-existing sleep disorder, but because the medication has structurally altered the brain's sleep regulation in ways that make unaided sleep difficult.

Next-Day Impairment

The FDA has set gender-specific dosing recommendations for zolpidem specifically because women metabolize the drug more slowly, leading to higher blood concentrations in the morning and increased risk of next-day impaired driving. Studies have found that blood levels sufficient to impair driving are present in a significant proportion of users the morning after a nighttime dose of standard zolpidem. Extended-release formulations carry even greater next-day impairment risk.

Dual Orexin Receptor Antagonists: The Newest Class

Suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) are the newest approved sleep medications. Rather than globally sedating the nervous system through GABA enhancement, they block the orexin system — the brain's wakefulness-promoting pathway. The pharmacological rationale is more targeted: insomnia is framed as excessive wakefulness signaling rather than insufficient sedation.

The orexin antagonists have a better safety profile than benzodiazepines and Z-drugs in several respects: lower risk of physical dependence, no evidence of next-day driving impairment at approved doses, and a generally more favorable adverse effect profile in older adults. However, they are not without risk.

Sleep Paralysis and Hypnagogic Hallucinations

Clinical trials of orexin receptor antagonists have documented increased rates of sleep paralysis (temporary inability to move upon awakening) and hypnagogic hallucinations (vivid hallucinations at sleep onset) compared to placebo. These effects are related to the REM-sleep-promoting mechanism of the drugs and are distressing for affected patients, though they are generally benign.

Worsening of Depression

Patients with depression or suicidal ideation may experience worsening of depressive symptoms on orexin antagonists. The FDA labeling includes a warning that these drugs should be used with caution in patients with psychiatric disorders. The orexin system is involved in mood regulation, and dampening it pharmacologically may have negative effects in vulnerable individuals.

Over-the-Counter Sleep Aids: A Dangerous Comfort

The most widely used sleep medications in America are not prescription drugs — they are the antihistamine-based sleep aids available on any pharmacy shelf: diphenhydramine (Benadryl PM, ZzzQuil, Unisom SleepTabs) and doxylamine (Unisom SleepMelts). These drugs are generally regarded as benign because they do not require a prescription. This perception is significantly out of step with their actual risk profile.

Anticholinergic Effects and Cognitive Risk

Diphenhydramine and doxylamine are anticholinergic drugs — they block acetylcholine receptors throughout the brain and body. Acetylcholine is essential for memory formation, attention, and cognitive function. Chronic anticholinergic drug exposure has been associated in large epidemiological studies with accelerated cognitive decline and increased dementia risk. A landmark study in JAMA Internal Medicine in 2015 found that cumulative use of anticholinergic drugs, including diphenhydramine, was associated with a significantly elevated risk of dementia in a dose-response relationship — higher cumulative exposure correlated with higher risk.

Rapid Tolerance Development

Tolerance to the sedating effects of antihistamine sleep aids develops within three to five nights of consecutive use. Most users find that OTC sleep aids that worked well initially produce diminishing returns within a week. The package labeling for these drugs specifically states they should not be used for more than two weeks, a warning that is routinely ignored. Users who continue taking them after tolerance develops are accepting anticholinergic drug exposure with no remaining sleep benefit.

Morning Grogginess

Diphenhydramine has a half-life of seven to twelve hours, meaning a dose taken at bedtime may still be pharmacologically active well into the following day. The "hangover" effect — morning grogginess, cognitive fog, dry mouth, and blurred vision — is a direct consequence of ongoing anticholinergic activity. This impairment can affect driving safety and cognitive performance the morning after use.

Melatonin: Benefits and Limitations

Melatonin is not a sedative — it is a chronobiotic hormone that signals the brain about the timing of the light-dark cycle. Its appropriate use is narrow: adjusting the timing of sleep in circadian rhythm disorders (jet lag, shift work, delayed sleep phase syndrome) rather than treating difficulty falling or staying asleep in people whose circadian timing is normal.

The evidence for melatonin in chronic insomnia with normal circadian timing is weak. Studies consistently show small-to-modest effects on sleep onset latency — perhaps five to ten minutes faster sleep onset on average — with no significant effect on sleep maintenance, total sleep time, or sleep efficiency. For chronic insomnia, the effects of melatonin are far smaller than those produced by CBT-I or even most prescription sleep medications.

Safety concerns with melatonin center primarily on dosing. The U.S. market has no regulatory constraint on melatonin doses, and most products contain doses dramatically higher than those used in clinical research (typically 0.3 to 1 mg) — commonly 5 mg, 10 mg, or even 20 mg. A 2023 study published in JAMA found that melatonin gummies in particular often contained substantially more melatonin than labeled, with some products containing over five times the labeled dose. Supraphysiological melatonin doses may suppress the body's own melatonin production, disrupt other hormonal systems, and — particularly in children — have unknown long-term developmental effects.

The Case for Non-Pharmacological First-Line Treatment

The American College of Physicians, the American Academy of Sleep Medicine, and the European Sleep Research Society all recommend CBT-I as the first-line treatment for chronic insomnia, placing pharmacological interventions as second-line options for cases where behavioral treatment is insufficient or inaccessible.

This hierarchy reflects both the evidence base and the risk profile. CBT-I produces comparable short-term outcomes to medication, superior long-term durability, and carries no risk of tolerance, dependence, withdrawal, cognitive impairment, or complex sleep behaviors. For the approximately 70 to 80 percent of chronic insomnia patients who respond to CBT-I, the behavioral approach achieves resolution of the disorder without the ongoing risks of pharmacological treatment.

For people who have already started sleep medications, CBT-I can serve as the foundation for supervised tapering. Research shows that patients who complete CBT-I while tapering medication are significantly more successful at discontinuing medication than those who attempt to taper without behavioral support.

Frequently Asked Questions

Are prescription sleep medications ever appropriate?

Yes. For acute, situational insomnia — insomnia triggered by a specific stressor, illness, or life event — short-term prescription sleep medication can be appropriate and helpful. The risks outlined in this article are primarily associated with long-term or chronic use. The clinical consensus is that pharmacological treatment should be time-limited, used at the lowest effective dose, and combined with behavioral interventions where possible.

What's the safest sleep medication available?

Among prescription sleep medications, the dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) have the most favorable safety profile for most adults, with lower dependence risk than benzodiazepines or Z-drugs and better-than-average tolerability in older adults. Among supplements, low-dose melatonin (0.3–1 mg) has a good safety profile for circadian-related sleep timing issues. OTC antihistamines (diphenhydramine, doxylamine) carry more risk than most people realize and should not be used chronically.

How do I stop taking sleep medication I've been using for a long time?

Stopping chronic sleep medication should be done gradually and under medical supervision. Abrupt discontinuation of benzodiazepines can cause serious withdrawal. A structured taper over weeks or months, combined with CBT-I to build non-pharmacological sleep skills, is the safest and most effective approach. Discuss a tapering plan with your prescribing physician before making any changes.

Is melatonin safe for long-term use?

Melatonin at low doses (0.3–1 mg) has a reasonable short-term safety profile, but long-term data on chronic high-dose use is limited. The doses in most U.S. commercial products (5–10 mg) far exceed those studied in clinical trials. For chronic insomnia with normal circadian timing, melatonin has limited efficacy and CBT-I is a more appropriate intervention.

The Evidence-Based Alternative to Long-Term Medication

The American College of Physicians recommends CBT-I before medication for chronic insomnia — and for people already on sleep medication, CBT-I is also the most effective tool for a successful taper. Sleep Reset is a digital CBT-I program that delivers individualized behavioral prescriptions with personal coaching support. It can be used concurrently with a supervised medication taper, building the non-pharmacological sleep skills that make discontinuation sustainable rather than simply uncomfortable.

Disclosure

Sleep Editorial is an independent publication. This article reflects the editorial team's independent assessment. Sleep Editorial does not provide medical advice; consult a qualified clinician for diagnosis and treatment.